S. Abraham, D. Waterhouse, and L. Mayer, The Liposomal Formulation of Doxorubicin, Methods in enzymology, vol.391, pp.71-97, 2005.
DOI : 10.1016/S0076-6879(05)91004-5

M. Aladdin and M. Et-ilyas, Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Beads Complicated by Interstitial Pneumonitis, Seminars in Interventional Radiology, vol.28, issue.02, pp.218-221, 2011.
DOI : 10.1055/s-0031-1280668

D. Alberts and D. Garcia, Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei Krebspatienten, Drugs, vol.54, issue.Supplement 4, pp.30-35, 1997.
DOI : 10.2165/00003495-199700544-00007

A. and H. Inca, Méthodologie générale d'élaboration des protocoles thérapeutiques hors GHS, 2007.

J. Burke, . Jr, J. Laucius, and H. Brodovsky, Doxorubicin hydrochloride-associated renal failure. Archive of internal medicine, pp.385-388, 1977.
DOI : 10.1001/archinte.137.3.385

M. Cain, G. Burton, and R. Et-holcombe, Fatal leukoencephalopathy in a patient with non-Hodgkin's lymphoma treated with CHOP chemotherapy and high-dose steroids. The American journal of the medical sciences, pp.315-202, 1998.

T. Cannon, D. Lai, and D. Hirsch, Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?, The Oncologist, vol.17, issue.12, pp.1541-1546, 2012.
DOI : 10.1634/theoncologist.2011-0216

L. Cerruti, D. Lebel, and J. Et-bussières, Perception de la pharmacovigilance par les pharmaciens hospitaliers qu??b??cois, Annales Pharmaceutiques Fran??aises, vol.74, issue.2, 2015.
DOI : 10.1016/j.pharma.2015.07.001

A. Chanan-khan, J. Szebeni, and S. Savay, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil(R)): possible role in hypersensitivity reactions, Annals of Oncology, vol.14, issue.9, pp.1430-1437, 2003.
DOI : 10.1093/annonc/mdg374

H. Chang and M. Et-yeh, Clinical development of liposome-based drugs : formulation, characterization, and therapeutic efficacy, International journal of nanomedicine, issue.7, pp.49-60, 2012.

G. Charrois and T. Et-allen, Rate of biodistribution of STEALTH?? liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1609, issue.1, pp.1609-102, 2003.
DOI : 10.1016/S0005-2736(02)00661-2

V. Chey, X. Chopin-ialy, and C. Micol, Acute pancreatitis after transcatheter arterial chemoembolization for liver metastases of carcinoid tumors. Clinics and research in hepatology and gastroenterology, pp.583-585, 2011.

L. Commission-de and . Transparence, Avis de la Commission MYOCET 50 mg, poudre et préadjuvants pour solution à diluer de dispersion liposomale pour perfusion. 5 septembre, 2001.

L. Commission-de and . Transparence, Avis de la Commission CAELYX 2 mg/ml, solution à diluer pour perfusion, 2001.

L. Commission-de and . Transparence, Avis de la Commission CAELYX 2 mg/ml, solution à diluer pour perfusion, 2003.

L. Commission-de and . Transparence, Avis de la Commission CAELYX 2 mg/ml, solution à diluer pour perfusion, 2009.

E. Diamandidou, A. Buzdar, and T. Smith, Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience., Journal of Clinical Oncology, vol.14, issue.10, pp.2722-2730, 1996.
DOI : 10.1200/JCO.1996.14.10.2722

S. Delemasure, C. Vergely, and M. Zeller, Pr??vention de??la??cardiotoxicit?? des??anthracyclines??: approche fondamentale des??m??canismes mis en??jeu??; relations avec??les??donn??es cliniques, Annales de Cardiologie et d'Ang??iologie, vol.55, issue.2, pp.55-104, 2006.
DOI : 10.1016/j.ancard.2006.02.005

T. De-saint-pol and . L-'obésité-en-france, les écarts entre catégories sociales s'accroissent, INSEE Première, pp.1123-1127, 2007.

B. Dezube, Safety assessment: DOXIL (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma. DOXIL Clinical Series, pp.1-8, 1996.

S. Duggan and G. Keating, Pegylated Liposomal Doxorubicin, Drugs, vol.9, issue.6, pp.71-2531, 2011.
DOI : 10.1111/j.1468-1293.2008.00608.x

M. Edwards, R. Walker, and S. Vinnicombe, Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma, Annals of Oncology, vol.12, issue.9, pp.1327-1329, 2001.
DOI : 10.1023/A:1012248800195

M. Faculté-de, M. Pierre, and . Curie, Biochimie : structure des glucides et lipides [en ligne], disponible sur, p.905, 2015.

P. Faggioli, M. De-paschale, and A. Tocci, Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma, Haematologica, vol.82, pp.38-42, 1997.

A. Gabizon, Stealth liposomes and tumor targeting : one step further in the quest for the magic bullet, Clinical cancer research, issue.7, pp.223-225, 2001.

A. Gabizon, Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy, Cancer Investigation, vol.58, issue.11, pp.424-436, 2001.
DOI : 10.1016/B978-044482917-7/50035-1

A. Gabizon, H. Shmeeda, and Y. Et-barenholz, Pharmacokinetics of Pegylated Liposomal Doxorubicin, Clinical Pharmacokinetics, vol.11, issue.5, pp.419-436, 2003.
DOI : 10.2165/00003088-200342050-00002

A. Gabizon, H. Shmeeda, and T. Et-grenader, Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy, European Journal of Pharmaceutical Sciences, vol.45, issue.4, pp.388-398, 2012.
DOI : 10.1016/j.ejps.2011.09.006

J. Keeney, S. Miriyala, and T. Noel, Superoxide induces protein oxidation in plasma and TNF-?? elevation in macrophage culture: Insights into mechanisms of neurotoxicity following doxorubicin chemotherapy, Cancer Letters, vol.367, issue.2, pp.157-161, 2015.
DOI : 10.1016/j.canlet.2015.07.023

A. Kim, K. Yoo, and K. Lee, A Case of Cryptogenic Organizing Pneumonia after Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. Tuberculosis and respiratory disease, pp.78-469, 2015.

L. Kun and B. Et-camitta, Hepatopathy following irradiation and adriamycin, Cancer, vol.117, issue.1, pp.81-84, 1978.
DOI : 10.2214/ajr.117.1.73

URL : http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197807)42:1<81::AID-CNCR2820420113>3.0.CO;2-K/pdf

N. La-beck, B. Zamboni, and A. Gabizon, Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients, Cancer Chemotherapy and Pharmacology, vol.66, issue.4, pp.43-50, 2012.
DOI : 10.1007/s00280-010-1406-x

T. Lahoti, D. Patel, and V. Thekkemadom, Doxorubicin-Induced In Vivo Nephrotoxicity Involves Oxidative Stress- Mediated Multiple Pro- and Anti-Apoptotic Signaling Pathways, Current Neurovascular Research, vol.9, issue.4, pp.282-295, 2012.
DOI : 10.2174/156720212803530636

A. Lansiaux and P. Et-pourquier, Mécanismes moléculaires et déterminants de la réponse aux inhibiteurs de topo-isomérases II, Bulletin du cancer, vol.98, issue.11, pp.1299-1310, 2011.

J. Lao, J. Madani, and T. Puértolas, Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review, Journal of Drug Delivery, vol.21, issue.1971, p.456409, 2013.
DOI : 10.1093/annonc/mdr519

R. Lauvin, L. Miglianico, and R. Et-hellegouarc-'h, Skin Cancer Occurring 10 Years after the Extravasation of Doxorubicin, New England Journal of Medicine, vol.332, issue.11, p.754, 1995.
DOI : 10.1056/NEJM199503163321117

R. Leonard, S. Williams, and A. Tulpule, Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet???), The Breast, vol.18, issue.4, pp.218-224, 2009.
DOI : 10.1016/j.breast.2009.05.004

A. Lorin, C. Flore, and A. Thomas, Les liposomes : description, fabrication et applications

D. Lorusso, D. Stefano, A. Carone, and V. , Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome) Annals of oncology, pp.1159-1164, 2007.

M. Lotem, A. Hubert, and O. Lyass, Skin Toxic Effects of Polyethylene Glycol???Coated Liposomal Doxorubicin, Archives of Dermatology, vol.136, issue.12, pp.1475-1480, 2000.
DOI : 10.1001/archderm.136.12.1475

O. Lyass, B. Uziely, and R. Ben-yosef, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, vol.13, issue.5, pp.1037-1047, 2001.
DOI : 10.1200/JCO.1995.13.4.996

B. Ma, W. Yeo, and P. Hui, Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer ??? a retrospective review of Chinese patients and comparison with an historic Western series, Radiotherapy and Oncology, vol.62, issue.2, pp.185-189, 2002.
DOI : 10.1016/S0167-8140(02)00003-8

L. Ma, G. Taylor, and M. Wharam, "Recall" pneumonitis: adriamycin potentiation of radiation pneumonitis in two children., Radiology, vol.187, issue.2, pp.465-467, 1993.
DOI : 10.1148/radiology.187.2.8475291

J. Mangana, M. Zipser, and C. Conrad, Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome, European journal of dermatology, vol.18, pp.566-570, 2008.

D. Mani, R. Dorer, and D. Et-aboulafia, Therapy-Related Acute Myeloid Leukemia Following HIV-Associated Lymphoma, Clinical Lymphoma and Myeloma, vol.9, issue.4, pp.316-319, 2009.
DOI : 10.3816/CLM.2009.n.062

. Martindale, The Complete Drug Reference. 38 ème édition, pp.783-786, 2014.

K. Matsuo, E. Blake, and A. Yessaian, Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer. The oncologist, pp.1598-1599, 2012.

G. Mayer and D. Et-hudrisier, Le complément In : Immunologie, mise à jour 10, p.5, 2012.

D. Mcinerney and J. Et-bullimore, Reactivation of radiation pneumonitis by adriamycin. The British journal of radiology, pp.224-227, 1977.

M. Mian, I. Wasle, and G. Gamerith, are they really equally effective ? Clinical oncology, pp.648-652, 2014.

R. Minow, M. Stern, and J. Casey, Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and adriamycin, Cancer, vol.28, issue.4, pp.1524-1528, 1976.
DOI : 10.1002/cpt1975184462

N. Nevadunsky, C. Mbagwu, and N. Mizrahi, Pulmonary Fibrosis After Pegylated Liposomal Doxorubicin in a Patient With Uterine Papillary Serous Carcinoma, Journal of Clinical Oncology, vol.31, issue.10, pp.31-167, 2013.
DOI : 10.1200/JCO.2012.44.5767

M. Palm, D. Moneret-vautrin, and G. Kanny, Food allergy to egg and soy lecithins, Allergy, vol.28, issue.10, pp.1116-1117, 1999.
DOI : 10.1046/j.1365-2222.1998.00431.x

A. Patakfalvi, E. Gelencsér, and J. Et-sípos, Drug hepatitis of cholestatic type in association with a FAC-regimen for breast cancer, Acta medica hungarica, vol.44, pp.377-385, 1987.

M. Pezzoli, M. Galvagno, and G. Et-bongioannini, Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer, Case Reports, vol.18, issue.(Suppl), p.3, 2015.
DOI : 10.3109/09273940903374237

D. Plats, M. Baudrant, and V. Et-ratsimbazafy, Liposomes et formes p??gyl??es : revue des m??dicaments disponibles, Actualit??s Pharmaceutiques Hospitali??res, vol.1, issue.3, pp.46-60, 2005.
DOI : 10.1016/S1769-7344(05)70079-2

F. Puisieux, M. Seiller, and J. Et-devissaguet, Les syst??mes de d??livrance des m??dicaments : un r??el progress pour la th??rapeutique*, Annales Pharmaceutiques Fran??aises, vol.64, issue.4, pp.219-259, 2006.
DOI : 10.1016/S0003-4509(06)75318-4

G. Randon, M. Nicoletto, and N. Milite, Squamous Cell Carcinoma of the Oral Cavity in a Woman With a 9-Year History of Ovarian Cancer: Is Exposure to Pegylated Liposomal Doxorubicin a Factor?, The Oncologist, vol.19, issue.4, p.429, 2014.
DOI : 10.1634/theoncologist.2013-0421

I. Ruiz and C. Et-féray, Prise en charge du carcinome h??patocellulaire, Cancer/Radioth??rapie, vol.19, issue.6-7, pp.410-415, 2015.
DOI : 10.1016/j.canrad.2015.05.008

T. Safra, Cardiac safety of liposomal anthracyclines. The oncologist, pp.17-24, 2003.

J. Schlangen and J. Et-wils, Liver calcifications following hepatic artery infusion with 5- fluorouracil, adriamycin and mitomycin C (FAM). Röfo, pp.607-608, 1984.

C. Shapiro, T. Ervin, and L. Welles, Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer, Journal of Clinical Oncology, vol.17, issue.5, pp.1435-1441, 1999.
DOI : 10.1200/JCO.1999.17.5.1435

Y. Shi, M. Moon, and S. Dawood, Mechanismen und Management der Doxorubicinkardiotoxizt??t, Herz, vol.334, issue.4, pp.296-305, 2011.
DOI : 10.1124/jpet.110.170191

V. Sibaud, J. Fricain, and R. Baran, Anomalies pigmentaires induites par les traitements anticanc??reux. Premi??re partie??: les chimioth??rapies, Annales de dermatologie et de vénéréologie, pp.183-196, 2013.
DOI : 10.1016/j.annder.2012.12.012

I. Sino-biological, Complement activation pathways [en ligne], disponible sur : www.sinobiological.com (page consultée le 03, 2015.

L. Smith, V. Cornelius, and C. Plummer, Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials, BMC Cancer, vol.112, issue.6, p.337, 2010.
DOI : 10.1161/CIRCULATIONAHA.105.576850

L. Soh, P. Ang, and I. Sng, Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy, European Journal of Cancer, vol.28, issue.8-9, pp.28-1338, 1992.
DOI : 10.1016/0959-8049(92)90513-2

D. Solimando, . Jr, and J. Et-wilson, Doxorubicin-induced hypersentivity reactions. Drug intelligence and clinical pharmacy, pp.808-811, 1984.

R. Soloman and A. Et-gabizon, Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin, Clinical Lymphoma and Myeloma, vol.8, issue.1, pp.21-32, 2008.
DOI : 10.3816/CLM.2008.n.001

G. Song, H. Wu, and K. Yoshino, Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs, Journal of Liposome Research, vol.86, issue.3, pp.177-192, 2012.
DOI : 10.1038/clpt.2009.141

S. Swain, F. Whaley, and M. Et-ewer, Congestive heart failure in patients treated with doxorubicin, Cancer, vol.150, issue.11, pp.97-2869, 2003.
DOI : 10.1111/j.1749-6632.1982.tb31279.x

C. Swenson, W. Perkins, and P. Roberts, Liposome technology and the development of Myocet (liposomal doxorubicin citrate) The breast, pp.1-7, 2001.

J. Szebeni, Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals, Molecular Immunology, vol.61, issue.2, pp.61-163, 2014.
DOI : 10.1016/j.molimm.2014.06.038

J. Szebeni, F. Muggia, and A. Gabizon, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products : Prediction and prevention. Advanced drug delivery reviews, pp.1020-1030, 2011.

M. Sznol, T. Ohnuma, and J. Et-holland, Hepatic Toxicity of Drugs Used for Hematologic Neoplasia, Seminars in Liver Disease, vol.7, issue.03, pp.237-256, 1987.
DOI : 10.1055/s-2008-1040580

O. Tacar, P. Sriamornsak, and C. Et-dass, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems, Journal of Pharmacy and Pharmacology, vol.31, issue.2, pp.157-170, 2013.
DOI : 10.1016/j.biomaterials.2009.09.069

A. Templeton, K. Ribi, and C. Surber, Prevention of palmar???plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08), The Breast, vol.23, issue.3, pp.244-249, 2014.
DOI : 10.1016/j.breast.2014.02.005

. Thériaque and . In, Recherche simple [en ligne], disponible sur : http://www.theriaque.org/apps/monographie/index, pp.7949-7967, 2015.

. Thériaque and . In, Recherche simple [en ligne], disponible sur : http://www.theriaque.org/apps/monographie/index.php?, pp.14168-14186, 2015.

. Thériaque and . In, Recherche simple [en ligne], disponible sur : http://www.theriaque.org/apps/monographie/index.php?, pp.10439-10457, 2015.

P. Vejpongsa and E. Et-yeh, Prevention of Anthracycline-Induced Cardiotoxicity, Journal of the American College of Cardiology, vol.64, issue.9, pp.938-945, 2014.
DOI : 10.1016/j.jacc.2014.06.1167

P. Volkow, M. Lizano, and A. Carrillo-garcía, Triple secondary neoplasms, AIDS, vol.28, issue.15, pp.2327-2329, 2014.
DOI : 10.1097/QAD.0000000000000420

V. Moos, R. Thuerlimann, B. Aapro, and M. , Pegylated liposomal doxorubicin-associated hand-foot syndrome : recommendations of an international panel of experts, European journal of cancer, pp.44-781, 2008.

F. Wapstra, H. Van-goor, D. Jong, and P. , Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis, Journal of Pharmacological and Toxicological Methods, vol.41, issue.2-3, pp.69-73, 1999.
DOI : 10.1016/S1056-8719(99)00015-5

I. Wasle, G. Gamerith, and F. Kocher, Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial, Annals of Hematology, vol.21, issue.7, pp.593-601, 2015.
DOI : 10.1093/annonc/mdp544

Y. Yuan, S. Orlow, and J. Curtin, Pegylated Liposomal Doxorubicin (PLD): Enhanced skin toxicity in areas of vitiligo, ecancermedicalscience, vol.3, issue.2, p.111, 2008.
DOI : 10.3332/ecancer.2008.111

N. Yokomichi, T. Nagasawa, and A. Coler-reilly, Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin, Human Cell, vol.44, issue.1, pp.8-18, 2013.
DOI : 10.1038/nm1758

L. Zappa, R. Savady, and G. Humphries, Interstitial pneumonitis following intrapleural chemotherapy, World Journal of Surgical Oncology, vol.7, issue.1, p.17, 2009.
DOI : 10.1186/1477-7819-7-17

URL : https://wjso.biomedcentral.com/track/pdf/10.1186/1477-7819-7-17?site=wjso.biomedcentral.com